OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
From little subclones grow mighty oaks	1340
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	1303
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	913
Sacituzumab govitecan plus pembrolizumab improves outcomes	904
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	867
A new standard of care for advanced-stage urothelial carcinoma	736
Novel ICI–TKI combination improves HCC outcomes	715
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	633
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	594
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	589
Ecological management of the microbiota in patients with cancer	552
Hodgkin lymphoma: great progress with room for improvement	540
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	524
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	510
Gut microbiota in colorectal cancer development and therapy	503
Current understanding and management of CAR T cell-associated toxicities	495
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	436
Ponatinib superior to imatinib in Ph+ ALL	408
Mortality is similar with active monitoring	373
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	352
From ESMO 2022	352
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	350
Belzutifan as a new option in pheochromocytomas and paragangliomas	350
Sacituzumab tirumotecan improves OS in mTNBC	342
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	342

Humanized mouse models for immuno-oncology research	341
Emerging trends in the global burden of colorectal cancer	341
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	334
Understanding and overcoming multidrug resistance in cancer	330
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	314
Biomarkers for immunotherapy of hepatocellular carcinoma	305
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	286
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	283
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	279
Vebreltinib effective in MET-amplified NSCLC	266
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	264
Improving outcomes in patients with oesophageal cancer	264
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	264
Spatial landscapes of cancers: insights and opportunities	231
MicroRNAs in oncology: a translational perspective in the era of AI	227
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	218
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	216
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	206
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	206
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	202
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	196
Women with clinically node negative breast cancer can safely avoid axillary surgery	184
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	182
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	182
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	177
Prospective comparisons support the use of navigational bronchoscopy	171
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	155
DREAMseq of therapy for BRAF-mutant melanoma	154
From ESMO 2023: advances in lung cancer	153
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA	149
Targeting chromosomal instability in patients with cancer	149
Synergistic integration of regional and systemic therapies in uveal melanoma	144
Circulating tumour DNA — looking beyond the blood	142
Mitigating acute chemotherapy-associated adverse events in patients with cancer	138
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	132
Long-term outcomes following CAR T cell therapy: what we know so far	132
Multiomics STEP up in correlative analysis of response to CAR T cells	130
From the ESMO Congress 2023	129
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	127
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	126
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	124
Sentinel lymph node biopsy improves surgical management of cervical cancer	121
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	120
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	117
Author Correction: Innovative approaches for lung cancer screening and interception	115
Lung cancer in patients who have never smoked — an emerging disease	114
Newly approved cancer drugs in China — innovation and clinical benefit	111
Enhancing immunotherapy with tumour-responsive nanomaterials	110
Targeted biopsy reduces detection of clinically insignificant cancer	110
Claudin 18.2 as a novel therapeutic target	110

Clinical implications of T cell exhaustion for cancer immunotherapy	110
T-DXd effective as second-line therapy in G/GEJ cancers	108
Second-line tarlatamab improves OS in SCLC	106
Less-frequent surveillance is noninferior to annual mammography	105
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	103
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	103
Translating biological insights into improved management of endometrial cancer	98
Patient value over patent value: the mandate for open-source oncology	94
Barriers in access to oncology drugs — a global crisis	90
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	89
Two decades of advances in clinical oncology — lessons learned and future directions	87
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	85
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	82
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	81
BrECADD raises the bar in classical Hodgkin lymphoma	81
HSCT prolongs remission of high-risk CTCLs	80
Thermal ablation is safer than resection of colorectal liver lesions	77
Promising OS with oncolytic virotherapy	77
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	74
GPRC5D-CAR T cells active in MM	71
Promise with co-administration of CAR T cells	70
Efficacy of TILs confirmed	67
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	66
Non-financial conflicts of interest	64
Nirogacestat effective in desmoid tumours	64
Cured but breathless: the growing burden of DIILD in cancer survivors	64
Multidisciplinary management of meningiomas in the era of precision oncology	61
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	61
Engineering platelets as cancer therapeutics	59
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	58
Exploiting bacteria for cancer immunotherapy	52
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	51
The current state of the art and future trends in RAS-targeted cancer therapies	51
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management	47
KN046 shows tolerability and activity in TNBC	46
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
Problematic crossovers in cancer drug trials	45
Clinical implementation of multi-cancer early detection tests: can we find a path forward?	44
Neoadjuvant pembrolizumab improves outcomes	44
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	42
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	42
Realizing the benefits of tumour-agnostic access requires a national health learning system	41
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	41
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	38
The emerging roles of γδ T cells in cancer immunotherapy	38
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	36
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	36
The changing landscape of oncology clinical trials in Latin America	35
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	34
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	33
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	33
GPRC5D as a novel immunotherapeutic target in multiple myeloma	33
CAR T cells induce durable remission of neuroblastoma	33
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons	33
National value-based pricing negotiation for oncology drugs — lessons from China	33
Personalizing adjuvant therapy for patients with colorectal cancer	32